The substance identified as Qingwen Baidu Powder Veterinary Grade API is a multi-herb extract standardised for incorporation into tablets, injections, capsules, powders, granules, premixes, and oral solutions. The product designation does not include a separate numerical model; the full name string is used as the identifier on certificates of analysis and batch release documentation. This composite extract is not a single synthetic molecule, and batch-to-batch consistency is therefore assessed by chromatographic fingerprinting rather than by a single purity assay. Published data for this specific configuration is limited; the release criteria below represent the manufacturer’s documented specification matrix for the multi-dosage form grade and are derived from general veterinary botanical API monographs and compendial methods. The operational parameters described in this introduction are typical for this formulation class and should be confirmed against the manufacturer’s current batch documentation.

The API is supplied as a brown to tan powder. For injection-grade material, the powder is micronised and depyrogenated to control bacterial endotoxins and subvisible particulate matter. For oral solids, the particle size is adjusted to maintain blend uniformity and reduce segregation during direct compression and encapsulation. The specification matrix in the table below is applied at batch release.

The compendial methods referenced in the specification matrix are Ph. Eur. 2.2.32 for loss on drying, Ph. Eur. 2.4.16 for ash, Ph. Eur. 2.4.8 for heavy metals, Ph. Eur. 2.4.2 for arsenic, Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13 for microbial limits, Ph. Eur. 2.6.14 for bacterial endotoxins, USP ⟨429⟩ for laser-diffraction particle sizing, and USP ⟨616⟩ for bulk and tapped density.

How Is the API Qualified for Injection-Grade Use While Retaining Oral-Dosage Function?

The injection route imposes constraints not applicable to oral solids. For injectable formulations, the API is micronised to a volume mean diameter in the range 10–25 µm and then depyrogenated by activated-carbon adsorption followed by 0.2 µm tangential-flow filtration. Residual bacterial endotoxins are controlled below 0.5 EU/mg, and the finished sterile powder for injection is filled under Grade A aseptic conditions. Reconstituted solutions are tested for subvisible particles per USP ⟨788⟩. Because the multi-herb extract contains polysaccharides and proteins, aqueous solubility is limited; injectable formulations therefore require pH adjustment to 5.0–7.0 and may include propylene glycol at 10%–20% v/v as a co-solvent. Osmolality is adjusted with sodium chloride to 280–320 mOsm/kg when the formulation is administered intravenously. The oral-dosage function is retained by using the same extract core without the depyrogenation and micronisation sequence; the particle-size and density envelope for oral solids is controlled separately. For injectable use, the finished solution should be filtered through a 0.45 µm membrane before final sterilisation if the extract contains insoluble polysaccharide aggregates above 0.1% w/w. Published data for this specific configuration is limited, and terminal sterilisation compatibility must be confirmed with each new injection batch.

In tablet manufacture, the oral-grade API is blended with microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide in a bin blender at 25 rpm for 15 min. Magnesium stearate is then added at 0.5% w/w and blended for 3 min to prevent overlubrication and delayed dissolution. Blend uniformity is verified by sampling 10 locations and assaying the indicator component; acceptance is a relative standard deviation not exceeding 5.0%. For wet granulation, the API is granulated with a 5% w/w povidone solution at a spray rate of 8 g/min in a high-shear granulator with an impeller speed of 300 rpm and a chopper speed of 1500 rpm. The wet mass is dried in a fluid-bed dryer at inlet air temperature 60 °C to a final moisture content of 1.5%–2.5%. Compression is performed on a rotary tablet press with a main compression force of 8–12 kN; tablet hardness is maintained at 60–90 N, friability below 0.8% per USP ⟨1216⟩, and disintegration time below 15 min in water at 37 °C. The Hausner ratio should be below 1.35 and the compressibility index below 25% for direct compression candidates. Capsule filling of the powder blend is performed on an automatic tamping-pin capsule machine; the fill weight is set to deliver the target API dose with a uniformity acceptance of ±5% per USP ⟨905⟩. For granules and oral powders, the dried granulate is sieved through a 1000 µm screen and the fraction between 180 µm and 850 µm is collected; fines below 180 µm are limited to less than 15% w/w to reduce segregation during sachet filling.

When Premix and Drinking-Water Vehicles Require Different Particle-Size and Dispersibility Properties

For medicated feed premix production, the API is diluted with a feed-grade carrier such as calcium carbonate or rice hulls in a horizontal ribbon mixer at 60 rpm for 20 min. Mixer load must not exceed 70% of trough volume to prevent dead zones. The carrier blend is then incorporated into complete feed at rates between 0.5% and 2.0%; the coefficient of variation of the active marker after final mixing should be below 5%. Particle-size for premix grade is controlled with a D50 of 45–75 µm and a D90 not exceeding 150 µm to maintain homogeneity in mineral-heavy basal feeds. For drinking water solutions, the API is typically supplied as a water-dispersible powder that forms a suspension. Dispersibility is verified by adding 5 g to 1 L of water at 25 °C and stirring at 300 rpm for 10 min; the suspension should pass through a 75 µm screen without agglomeration. Sedimentation volume after 1 h should not exceed 1.5 mL per 100 mL when a suspending agent is included. The pH of the drinking-water dispersion is maintained between 5.0 and 7.0; below 4.5 acidic waterlines can protonate ionisable components and reduce chemical stability, while above 8.0 precipitation of calcium and magnesium salts from hard water may occur. The API should not be combined with chlorine-based waterline sanitisers at free chlorine concentrations above 2 mg/L, because oxidative degradation of polyphenols is accelerated under these conditions.

Relative to single-extract botanical APIs and synthetic small-molecule active substances, the Qingwen Baidu composite extract differs in three operational characteristics. The composite requires multiple indicator markers for batch release, it carries a higher inherent ash and endotoxin burden that must be controlled for injectable use, and it exhibits broader formulation compatibility across the seven listed dosage forms because the extract can be processed into either micronised sterile powder or controlled-particle oral granule fractions. The comparative matrix is provided in the table below.

Unlike a synthetic small-molecule API with a single polymorph and a defined melting point, the composite extract is standardised by chromatographic fingerprinting and loss on drying. Published data for this specific configuration is limited; the information in the comparative table is based on general material class behaviour and manufacturer’s release documentation.

Compatibility Boundaries With Ionophores, Acidified Carriers, and Live Bacterial Therapeutics

The composite extract should be screened for compatibility before co-formulation with ionophore coccidiostats such as monensin or salinomycin, because high-ash plant extracts can alter gastric pH and mineral binding in the feed. When the API is administered in acidified waterlines using citric acid or phosphoric acid, the pH must be maintained above 4.5 to avoid precipitation of acidic phenolics. Concurrent administration with live bacterial therapeutics such as Bacillus subtilis or Enterococcus faecium should be separated by at least 4 h, because the extract’s organic acid and polyphenol fraction may reduce vegetative cell viability. The API is not recommended for sterile aqueous admixture with calcium gluconate or magnesium sulfate solutions; incompatibility is indicated by visible flocculation within 2 h at 25 °C. Avoid combination with amine-based solubilisers at pH above 8.0 due to accelerated oxidative darkening and loss of marker peaks. For all dosage forms, moisture-sensitive processing must be controlled at relative humidity below 60%; above this threshold the powder absorbs atmospheric moisture and may exhibit decreased flow and increased sticking during compression. Published data for some co-formulation combinations is limited, and a benchtop compatibility screen is required before batch manufacture.